Acute Coronary Syndrome
Conditions
Brief summary
This registry has the aim to assess the use of different antithrombotic therapies, including untested drug combinations, routinely used during the hospitalization phase, with their timing, route and dose of administration, in consecutive patients discharged with a diagnosis NSTEMI or STEMI in Italian Cardiac care Units (CCUs) during a four-week study period.
Detailed description
EYESHOT-2 is a prospective, multicenter, observational, nationwide survey of patients discharged with a diagnosis NSTEMI or STEMI admitted to Italian CCUs. The survey will be designed to include all consecutive patients, who met the eligibility criteria, admitted in hospitals with or without cardiac catheterization laboratories and cardiac surgery facilities during a period of 4 weeks.
Interventions
None listed
Sponsors
Heart Care Foundation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* All consecutive patients aged 18 years or more, discharged with diagnosis of myocardial infarction (NSTEMI or STEMI) admitted to CCUs undergoing myocardial revascularization (PCI or CABG) or conservative treatment. At presentation, the diagnosis of NSTEMI will be based on the measurement of troponins and assessment of ECG changes, as suggested by European Society of Cardiology (ESC) guidelines; the diagnosis of STEMI will be characterized by an acute chest pain and persistent (\>20 min) ST-segment elevation ≥ 1mm in two or more limb leads, or contiguous pre-cordial leads or left bundle branch block. * Written informed consent signed. Patients who cannot provide the informed consent due to very severe clinical conditions can give their consent some hours/days after admission, when more favourable clinical conditions allow them to receive the appropriate information. Patients having died before giving informed consent may also be included unless the local Institutional Review Board (IRB) does not allow this procedure. In that case, it is strongly suggested to obtain relative(s) agreement through the collect of a signed informed consent.
Exclusion criteria
* Patients with a diagnosis of Unstable Angina, * Patients developing MI after PCI or CABG, * MI following non-cardiac surgery or traumatic causes, * Patients with chest pain without elevation of troponin, * Patients enrolled in Randomized Controlled Trial (RCTs), * Patients already enrolled into the study from another CCU
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antithrombotic therapies | 1 week | The primary objective of the study is to describe at a national level the different antithrombotic therapies (alone or in combination) commonly employed from admission to discharge in NSTEMI or STEMI patients undergoing different therapeutic strategies (PCI, CABG, conservative). A particular focus will be given to antithrombotic therapies (combinations, timing of administration, indications) used (a) before PCI (pre-treatment) (b) in the cath lab during PCI \[use of Glycoprotein IIb/IIIa inhibitors (GPIs), cangrelor, anticoagulants\] and (c) during hospital stay. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Assessment of in-hospital clinical events | 1 week | An exploratory objective is the assessment of the rate of in-hospital clinical events (ischemic and hemorrhagic) in a large setting of NSTEMI or STEMI patients admitted to CCUs treated with different revascularization strategies and combinations of antithrombotic agents. |
Countries
Italy
Outcome results
None listed